La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kura Oncology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kura Oncology..

Kura Oncology (NASDAQ:KURA) Azioni, Catena delle Opzioni

Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Kura Oncology Inc

Kura Sushi Inc

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA Inc

Kuraray Co Ltd

Piper Sandler analyst Matt Farrell reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Overweight and raises the price target from $110 to $140.

News

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on Trade Desk, Raises Price Target to $140

Pineapple Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) ("Pineapple" or the "Company"), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that it will distribute to the holders of its non-transferable Contingent Value Rights ("CVRs") a payment of $850,269, or $0.35 per CVR.

Dividends

PEGY

Pineapple Energy Announces That It Will Distribute To The Holders Of Its Non-Transferable Contingent Value Rights A Payment Of $850,269, Or $0.35 Per CVR

WIIM

INDI

Indie Semiconductor shares are trading higher after the company reported better-than-expected Q3 financial results.

Scotiabank analyst Patrick Colville maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Sector Outperform and lowers the price target from $135 to $133.

DDOG

Scotiabank Maintains Sector Outperform on Datadog, Lowers Price Target to $133

Servotronics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVT#AMEX">SVT</a>) reported quarterly losses of $(0.20) per share. This is a 122.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $12.43 million in sales this quarter. This is a 7.32 percent increase over sales of $11.58 million the same period last year.

Earnings

Servotronics Q3 EPS $(0.20) Down From $(0.09) YoY, Sales $12.43M Up From $11.58M YoY

RVNC

Revance Therapeutics shares are trading lower after the company reported better-than-expected Q3 EPS results.

Piper Sandler analyst Alexander Potter maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Neutral and raises the price target from $16 to $18.

ACVA

Piper Sandler Maintains Neutral on ACV Auctions, Raises Price Target to $18

The holiday season brings joy, family gatherings and sometimes, stress.
For those considering cannabis as a natural way to ease holiday nerves and connect with loved ones, one of Vermont's largests cannabis brands, Upstate Elevator Supply Co. has introduced the Happy Days and Dreamy Nights THC gummy bundle. With a mix of daytime and nighttime formulas, this set of microdosed gummies offers an option for a balanced, relaxing holiday experience.
See Also: <a href="https://www.benzinga.com/markets/cannabis/22/01/24922189/report-americans-are-celebrating-traditional-holidays-with-cannabis-spend-millions-doing-so">Report: Americans Are Celebrating Traditional Holidays With Cannabis, Spend Millions Doing So</a>
In this guide, we'll walk you through practical tips from Kelsy Raap, a certified community herbalist and Upstate's director of outreach and education, on how to incorporate cannabis into your holiday gatherings.
<h3 class="wp-block-heading">Microdosing 101: How To Start Small</h3>
For those trying cannabis edibles for the first time, particularly in a family setting, Raap recommends beginning with a microdose. "Start low," she advises. "One milligram is a good place to start for somebody that's never used cannabis or who doesn't use it regularly." 
Upstate's gummy pucks are pre-scored into precise 2mg wedges, allowing users to choose a small amount and adjust as needed. For newcomers, Raap suggests staying below 5mg, especially during social gatherings where moderation can make for a smoother experience.
To enhance the benefits while keeping the experience mellow, consider formulas that balance THC with other cannabinoids like CBD, CBG or CBN. "These compounds help balance the THC so that it doesn't feel quite as altering," Raap explains. For first-timers, this balance can provide all the therapeutic effects of THC without an overwhelming high.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1022" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-1022x1024.jpg" alt="" class="wp-image-636585" style="width:360px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-1022x1024.jpg 1022w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-300x300.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-150x150.jpg 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-768x769.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies.jpg 1078w" sizes="(max-width: 1022px) 100vw, 1022px" /><figcaption class="wp-element-caption">Image courtesy: Upstate Elevator.</figcaption></figure>
<h3 class="wp-block-heading">Easing Holiday Stress: How THC And CBD Work Together</h3>
Holiday stress is common, and for many, cannabis offers a natural way to manage it. Raap explains how the combined effects of CBD and THC can support relaxation, each working differently to calm the body and mind. 
"CBD, the non-intoxicating component, is great for helping us calm down, for helping sort of ease the mind in a very subtle, gentle way," she says. THC, on the other hand, can provide a more immediate sense of relaxation at low doses, making it a good choice for those who want to unwind without feeling overly sedated. Even a small amount, about one milligram, can soothe the nervous system and bring a sense of calm.
Microdosing THC, especially in social situations, can also help people take a step back from potentially tense conversations, adding a layer of objectivity. Raap notes that, at low doses, THC "helps us kind of zoom out, pull back, see things from a little bit more of a holistic perspective, and feel a little bit less personally involved in a conflict." For holiday gatherings where emotions might be heightened, especially after the U.S. elections, this approach can foster a more relaxed and open atmosphere.
<h3 class="wp-block-heading">Bringing Cannabis To The Family Table: How To Build Comfort And Trust</h3>
Cannabis at family occasions is gradually becoming more normalized, and Raap has seen this shift firsthand. 
 "One of my favorite things is when a customer walks into our store, who's, you know, 35, 40 years old, and they're bringing their parents in with them," she shares. This shift is often met with curiosity and surprise as parents rediscover cannabis, especially in a low-dose, controlled form.
Raap points out that today's cannabis products come with clear labeling and rigorous testing, which can ease the concerns of older generations. "There's a lot more trust in the companies now, right? Because everything is tested," she notes. 
For older adults, the transparency of listed ingredients and lab-tested dosages can offer peace of mind. These products are created to help bridge generations, allowing young adults to share the benefits of cannabis with their parents or grandparents in a safe, enjoyable way.
<h3 class="wp-block-heading">How to Talk Your Family Into Microdosing THC This Holiday Season</h3>
Introducing cannabis at family gatherings can be met with hesitation, but Raap offers a straightforward approach. "If a family is happy with the dynamics—if they&#8217;re mostly peaceful and calm, if they don&#8217;t have any challenges with fighting over politics or religion—then you don't need it." 
However, for families who find themselves in tense discussions or who want to keep things light, microdosing can be beneficial. "If a family is looking for a tool to help them have less reactivity during the holidays and be less reactive&#8230;this is a great tool."
For those worried about acting unpredictably, Raap reassures, "This isn't like alcohol, right? You're not going to make a fool of yourself if you use cannabis; you're not going to make poor decisions."
See Also: <a href="https://www.benzinga.com/markets/cannabis/19/04/13533938/a-really-nice-entry-point-cannabis-microdosing-and-who-its-for">&#8216;A Really Nice Entry Point&#8217;: Cannabis Microdosing And Who It&#8217;s For</a>
When legal concerns come up, Raap suggests focusing on the benefits. "Consider whether you're looking for the therapeutic application. There are different ways to use cannabis. You can use it therapeutically, you can use it recreationally."
<h3 class="wp-block-heading">Quick Tips For First-Time Edible Users</h3>
Here are Raap's top tips for a positive experience:
<ol>
<li>Start Low and Go Slow: For beginners, 1-2mg is a good starting point,and 5mg should be the upper limit for those less experienced with THC.</li>
<li>Balance with CBD: Look for formulas that blend THC with other cannabinoids like CBD to create a balanced effect.</li>
<li>Be Prepared for Too Much: If you or someone feels "too high," Raap suggests taking a large dose of CBD, which can help mitigate THC's psychoactive effects and bring you back to a more comfortable level. "Using a large dose of CBD will mitigate the psychoactivity," she says.</li>
</ol>
<h3 class="wp-block-heading">Beyond The Holidays: A Healthier Alternative To Alcohol</h3>
If you're considering cutting back on alcohol this New Year, cannabis may be a fun, non-alcoholic alternative. "I could still have three or four of these while my friends are drinking their six-pack of beer," Raap suggests, while pointing at one of Upstate&#8217;s THC beverages. 
THC allows for a festive mood without the dehydrating, hangover-inducing effects of alcohol, making it an appealing option for those looking to moderate their drinking habits.
THC can also help support mental wellness during the winter months. For those prone to seasonal depression or daily anxiety, Raap recommends a more consistent approach, integrating cannabis into a daily wellness routine. 
"For folks that experience anxiety and stress every single day…planning to implement a daily practice with CBD and or low-dose THC is a good idea," she explains. Microdosing daily or as needed can help build resilience against winter blues.
<h3 class="wp-block-heading">Will Cannabis Become The New Alcohol At Family Gatherings?</h3>
Looking toward the future, Raap says she hopes cannabis will eventually be as accepted as alcohol at family events. "Honestly, I think that alcohol eventually is going to go the way of cigarettes," she says.
However, she notes that federal legalization would likely be necessary for widespread acceptance. "A lot of people still trust the government, and if the government says it's bad for you, they believe it," Raap added.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39585412/hand-in-hand-progressive-reform-galvanizes-interest-in-microdosing-new-study-shows">Reform Is Pushing Curiosity In Microdosing, Study Shows</a></li>
</ul>
Cover image made with AI.

Cannabis

Exclusives

Markets

Interview

How To Microdose Cannabis For Stress-Free Holiday Season: Tips For Newcomers

Agilon Health shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform.

Scotiabank analyst Mario Saric maintains CROMBIE REAL STATE INVESTMENT TRUST (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRR#TSX">CRR</a>) with a Sector Outperform and raises the price target from C$16 to C$16.5.

TSX:CRR

Scotiabank Maintains Sector Outperform on CROMBIE REAL STATE INVESTMENT TRUST, Raises Price Target to C$16.5

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $71 to $75.

SOLV

Piper Sandler Maintains Neutral on Solventum, Raises Price Target to $75

MRVI

Maravai LifeSciences shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Initiation

Pre-Market Outlook

Trading Ideas

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PARA

PARAA

Paramount Global Co-CEO Says Paramount Plus On Track To Achieve Domestic Profitability In 2025

Scotiabank analyst Patrick Colville maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Sector Perform and raises the price target from $85 to $87.

Scotiabank Maintains Sector Perform on Cloudflare, Raises Price Target to $87

China&#8217;s central government announced a new fiscal stimulus package worth 6 trillion yuan ($840 billion) to ease local governments&#8217; hidden debt burdens. This expansive financial program, set to be implemented by the end of 2026, marks a significant move by Beijing to address mounting economic pressures and revive growth amid global uncertainties.
The new stimulus plan, confirmed by China&#8217;s Minister of Finance Lan Fo&#8217;an, will allocate around 2 trillion yuan annually to local authorities, CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/08/china-expected-to-announce-highly-anticipated-fiscal-stimulus-package.html" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41812585/datadog-beats-q3-estimates-margins-show-mixed-results" rel="noreferrer noopener">Datadog Beats Q3 Estimates, Margins Show Mixed Results</a>
Additionally, central authorities will issue 800 billion yuan annually in special local government bonds, totaling 4 trillion yuan over the next five years. These measures are part of a broader strategy to reduce local hidden debt from 14.3 trillion yuan to 2.3 trillion yuan by 2028.
U.S.-listed Chinese stocks&nbsp;Alibaba Group Holding.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>),&nbsp;JD.com, Inc.&nbsp;(NASDAQ:&nbsp;JD),&nbsp;Baidu, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>),&nbsp;NIO Inc.&nbsp;(NYSE:&nbsp;NIO),&nbsp;Li Auto Inc.&nbsp;(NASDAQ:&nbsp;LI),&nbsp;and XPeng Inc.&nbsp;(NYSE:&nbsp;XPEV)&nbsp;are trading lower Friday as the stimulus failed to impress the Street <a target="_blank" href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday" rel="noreferrer noopener">which expected over</a> 10 trillion yuan ($1.39 billion) in financial support, focused on local government debt and real estate.
The financial package comes as the Chinese economy faces lingering challenges, including a real estate market slump and weaker local government revenues post-pandemic. During a press briefing, Minister Lan emphasized the urgency of addressing hidden local debts, which have ballooned to an estimated 50-60 trillion yuan ($7-8.4 trillion), according to projections by Nomura. This new initiative aims to help local governments manage interest payments, potentially saving up to 300 billion yuan annually.
China&#8217;s parliament, the National People&#8217;s Congress, is expected to formally approve the increased debt issuance quotas during its current legislative session. The move follows recent stimulus discussions led by President Xi Jinping and earlier efforts by the People&#8217;s Bank of China, which included interest rate cuts to support the economy. Market analysts anticipate heightened fiscal support after Donald Trump&#8217;s election, which may reignite trade tensions between the U.S. and China.
China aims to counter potential <a target="_blank" href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday" rel="noreferrer noopener">&#8220;Trump shocks&#8221; on trade</a> with its latest fiscal move.
After Trump&#8217;s victory, Chinese stocks declined while U.S. markets surged. During his campaign, Trump suggested boosting tariffs on Chinese imports by up to 60%. Such hikes might slash Chinese exports to the U.S. by around $200 billion and cut one percentage point from China&#8217;s GDP, according to former economic planning official Zhu Baoliang, cited by CNBC.
Price Actions:&nbsp;At the last check on Friday, BABA stock is down 3.28% at $96.86 premarket. JD is down 3.44%, BIDU is down 2.20%, NIO is down 2.26%, LI is down 4.96%, and XPEV is down 2.74%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41812311/appian-projects-positive-adjusted-ebitda-boasts-strong-subscription-revenue-in-q3" target="_blank" rel="noreferrer noopener">Appian Projects Positive Adjusted EBITDA, Boasts Strong Subscription Revenue In Q3</a></li>
</ul>
Photo Via Shutterstock

Government

Regulations

Media

BABA

BIDU

China's Stimulus Plan Not Enough To Ignite Stocks

Kentucky Governor <a href="https://www.benzinga.com/topic/andy-beshear">Andy Beshear</a> (D) hailed the outcome of Tuesday's election as a decisive statement on medical cannabis reform. In an election process that had bipartisan and widespread support, voters in over 100 cities and counties across the state approved local measures to permit medical marijuana businesses in their towns and jurisdictions.
Beshear, <a href="https://www.benzinga.com/markets/cannabis/23/03/31612072/kentucky-becomes-38th-state-to-legalize-medical-marijuana-as-gov-beshear-signs-bill-into-law">who signed a medical marijuana legalization bill </a>into law last year, declared that the results confirm what many already believed: Kentuckians support cannabis reform.
"This signals what we have known for a long time, which is that the jury is no longer out on medical cannabis," Beshear <a href="https://www.kentucky.gov/Pages/Activity-stream.aspx?n=GovernorBeshear&amp;prId=2333">said</a> in his weekly new conference Thursday. "Kentuckians want their families, friends and neighbors who have serious medical conditions &#8211; like cancer, multiple sclerosis or PTSD &#8211; to have safe and affordable access. We are keeping our promise to make sure they will."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">Cannabis Reform Stumbles In 2024 Elections: A State-By-State Breakdown As Stocks Take A Hit</a>
All 53 cities and 53 counties presented with medical cannabis measures in Kentucky approved them, with over 340,000 votes cast in favor. This continues a trend in the state where more than 40 cities have already authorized marijuana businesses and only 20 jurisdictions have opted to ban them.
"We saw overwhelming support at the polls for our new system of medical cannabis," Beshear said, noting the uniform wins for the measures. "In every single place that medical cannabis was put on the ballot, it won &#8211; meaning citizens of every part of Kentucky said that it is time and they want to see this option in their community."
Of the state&#8217;s 106 ballot measures, no counties or cities opted to bar medical marijuana businesses from operating in their borders, according to data <a href="https://x.com/Hicks_JustinM/status/1854016544038158830">compiled </a>by Louisville Public Media&#8217;s Justin Hicks at WFPL News who <a href="https://x.com/WFPLNews">noted </a>that "every single county and every single city voted to approve medical cannabis businesses."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">According to my scraping of Kentucky local elections, &#x2A;every single county&#x2A; and &#x2A;every single city&#x2A; voted to approve medical cannabis businesses. <a href="https://t.co/FAVRN0HghV">pic.twitter.com/FAVRN0HghV</a>
&mdash; Justin Hicks (@Hicks_JustinM) <a href="https://twitter.com/Hicks_JustinM/status/1854016544038158830?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Kentucky stood apart in this year&#8217;s elections as <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">cannabis reform ballots failed </a>in North Dakota, South Dakota and Florida.
Kentucky&#8217;s new medical marijuana law will come into effect in January 2025. Preparations by the Office of Medical Cannabis (OCM) include <a href="https://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-marketshttps://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-markets">recent lotteries for approving</a> cultivators, processors and testing facilities, with a dispensary lottery scheduled for Dec. 16. Starting Dec. 1, physicians will be able to issue medical marijuana recommendations, and patients can begin applying for their cannabis cards on Jan. 1.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41829368/overdose-crisis-in-shadows-of-elections-as-black-indigenous-americans-deaths-rise">Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise</a></li>
</ul>
Government photo&nbsp;of Andy Beshear

Health Care

Legal

Kentucky Gov. Beshear: 'The Jury Is No Longer Out,' Kentuckians Want Medical Cannabis

Piper Sandler analyst Peter Keith reiterates YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Overweight and lowers the price target from $55 to $54.

YETI

Piper Sandler Reiterates Overweight on YETI Holdings, Lowers Price Target to $54

Scotiabank analyst Konark Gupta maintains Chorus Aviation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CHR#TSX">CHR</a>) with a Sector Perform and raises the price target from C$3.25 to C$3.4.

TSX:CHR

Scotiabank Maintains Sector Perform on Chorus Aviation, Raises Price Target to C$3.4

FTRE

Fortrea shares are trading higher after the company issued FY24 revenue guidance above estimates.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Kura Oncology (KURA) announced that two abstracts highlighting clinical data from the KOMET-007 combination trial of ziftomenib, the Company's pote...

Kura Oncology to present updated data from KOMET-007 trial

In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price ta...

Buy Rating for Kura Oncology Supported by Promising Ziftomenib Data and Strategic Drug Development

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology (KURA – Research Report). The associated price target...

Promising Outlook for Kura Oncology: Positive Phase 1 KOMET-007 Trial Results Support Buy Rating

Kura Oncology Q3 2024 Earnings Preview

Kura Oncology GAAP EPS of -$0.63 in-line

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating yesterday. Phil Nadeau has given his Buy rating...

Phil Nadeau Affirms Buy Rating on Kura Oncology Thanks to Promising Clinical Trials and Robust Financial Position

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology (KURA – Research Report) yesterday and set a price targe...

Kura Oncology Receives Buy Rating: Promising Developments in NPM1m AML Treatment and Attractive Valuation

In a report released today, George Farmer from Scotiabank maintained a Hold rating on Kura Oncology (KURA – Research Report), with a price target o...

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

BPMC

CATX

CGEM

CGON

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Press Releases

Kura Oncology Reports Second Quarter 2024 Financial Results

Kura Oncology to Participate in Cantor Global Healthcare Conference

Management

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

General

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Kura Oncology to Report Third Quarter 2024 Financial Results

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Comments

Kura Oncology

Kura Oncology (KURA) Opzioni

Kura Oncology (NASDAQ:KURA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO